» Articles » PMID: 39060946

GRASLND Regulates Melanoma Cell Progression by Targeting the MiR-218-5p/STAM2 Axis

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2024 Jul 26
PMID 39060946
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increasing evidence suggests that long noncoding RNAs (lncRNAs) play important regulatory roles in biological processes and are dysregulated in numerous tumors. The lncRNA GRASLND functions as an oncogene in many cancers, but its role in skin cutaneous melanoma (SKCM) requires further investigation.

Methods: SiRNA transfection, wound - healing and transwell assays were performed to evaluate the effect of GRASLND on cellular function.

Results: The present study demonstrated that GRASLND expression is increased in SKCM tissues and cell lines. The high expression of GRASLND was correlated with poor prognosis and immunotherapy outcomes. Knockdown of GRASLND significantly inhibited cell migration and invasion. In addition, we found that miR-218-5p directly binds to its binding site on GRASLND, and GRASLND and miR-218-5p demonstrate mutual inhibition. Furthermore, the miR-218-5p inhibitor partially eliminated the knockdown of GRASLND and inhibited its expression. We also demonstrated that GRASLND acts as a miR-218-5p sponge that positively regulates STAM2 expression in SKCM cells.

Conclusion: In summary, these data suggest that GRASLND functions by regulating miR-218-5p/STAM2 expression, suggesting an important role for the lncRNA‒miRNA-mRNA functional network and a new potential therapeutic target for SKCM.

Citing Articles

Construction of a tumor mutational burden-derived LncRNA prognostic computational framework associated with therapy sensitivity in skin cutaneous melanoma.

Li G, Wu T, Li H, Wei C, Sun Y, Gao P J Transl Med. 2024; 22(1):966.

PMID: 39449143 PMC: 11515383. DOI: 10.1186/s12967-024-05732-4.

References
1.
Zhu Y, He D, Bo H, Liu Z, Xiao M, Xiang L . The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway. Oncogene. 2019; 38(32):6065-6081. DOI: 10.1038/s41388-019-0858-7. View

2.
Fan Y, Sheng W, Meng Y, Cao Y, Li R . LncRNA PTENP1 inhibits cervical cancer progression by suppressing miR-106b. Artif Cells Nanomed Biotechnol. 2020; 48(1):393-407. DOI: 10.1080/21691401.2019.1709852. View

3.
Zeng H, Hou Y, Zhou X, Lang L, Luo H, Sun Y . Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer. Theranostics. 2022; 12(17):7351-7370. PMC: 9691361. DOI: 10.7150/thno.74753. View

4.
Bi H, Shang Z, Jia C, Wu J, Cui B, Wang Q . LncRNA RNF144A-AS1 Promotes Bladder Cancer Progression via RNF144A-AS1/miR-455-5p/SOX11 Axis. Onco Targets Ther. 2020; 13:11277-11288. PMC: 7649250. DOI: 10.2147/OTT.S266067. View

5.
Feng J, Zhang J, Li Y, Cheng W, Liu Y, Chen Z . Inhibition of lncRNA PCAT19 promotes breast cancer proliferation. Cancer Med. 2023; 12(10):11971-11982. PMC: 10242319. DOI: 10.1002/cam4.5872. View